LILRP2: A Potential Drug Target and Biomarker (G79166)

Target Name: LILRP2

NCBI ID: G79166

LILRP2

Other Name(s): leukocyte immunoglobulin-like receptor pseudogene 2 | Leukocyte immunoglobulin-like receptor pseudogene 2 | LILRA5 | ILT10 | CD85m

LILRP2: A Potential Drug Target and Biomarker

Leukocyte immunoglobulin-like receptor (LILRP2) is a gene that encodes a protein known as LILRP2, which is expressed in various tissues throughout the body. LILRP2 has been identified as a potential drug target and biomarker due to its unique structure and function.

The LILRP2 gene was first identified in the late 1990s as a gene that encodes a protein with 114 amino acid residues. The protein produced by this gene, LILRP2, is a cell surface protein that is involved in the immune response. It is expressed in various tissues, including the brain, heart, skeleton, and skin, and has been implicated in the development and progression of various diseases, including cancer, autoimmune diseases, and neurodegenerative disorders.

One of the key features of LILRP2 is its cytoplasmic expression. Unlike many other proteins, LILRP2 is not predominantly expressed in the cell nucleus, but is instead expressed in the cytoplasm. This is important because it suggests that LILRP2 may not be involved in intracellular signaling pathways, which could help to reduce the risk of developing drug-resistant strains.

Another potential drug target related to LILRP2 is its role in cell signaling. LILRP2 has been shown to play a role in regulating the immune response by controlling the movement of immune cells into the site of an infection or inflammation. Additionally, LILRP2 has been shown to Regulate the production of pro-inflammatory cytokines, which can contribute to the development of inflammatory diseases.

In addition to its potential drug target and biomarker properties, LILRP2 also has potential as a diagnostic biomarker. The LILRP2 gene has been shown to be expressed in various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. This suggests that LILRP2 may be a useful biomarker for these diseases, and that it may be possible to use LILRP2 as a target for new therapies.

In conclusion, LILRP2 is a gene that has potential as a drug target and biomarker. Its unique cytoplasmic expression and role in cell signaling make it an attractive target for new therapies. Further research is needed to fully understand the functions of LILRP2 and its potential as a drug and biomarker.

Protein Name: Leukocyte Immunoglobulin-like Receptor Pseudogene 2

The "LILRP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LILRP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets